Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zinc and new acid reducer tested in h. pylori battle

NCT ID NCT07275827

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This phase 3 trial will test how well two different triple therapies—one using a standard acid reducer (proton pump inhibitor) and one using a newer drug (vonoprazan)—work to eliminate H. pylori infection. It will also see if adding zinc improves results. The study plans to enroll 88 adults who test positive for H. pylori and will measure infection clearance and blood markers of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zinc sulfate, vonoprazan, amoxicillin, clarithromycin, proton pump inhibitor (omeprazole or pantoprazole)
What this could lead to
If successful, this study could show that adding zinc or using vonoprazan instead of a standard acid reducer improves H. pylori cure rates.
What could go wrong
This is a small, early-phase trial (88 people) that has not yet started. Results may not apply to everyone, and some people may have side effects from the antibiotics or zinc.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18. * Both males and females. * Patients who are positive for H.pylori infection by non-invasive Stool Antigen Test (SAT). Exclusion Criteria: * Prior H. pylori treatment: Previous treatment for H. pylori infection. * Allergies: Known allergies to study medications or components. * Patients cannot finish treatment course. * Pregnant and Lactating Women. * Patients with Kidney disease and eGFR \< 30ml/min. * Patients with Liver disease with Child-Pugh B or C.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Liver Institute

    RECRUITING

    Shibīn al Kawm, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.